









市場
/
株式
/
nasdaq-gild
/

Gilead Sciences Inc

GILD

105.930USD

-1.270-1.18%

終値 06/25, 16:00（ET）15分遅れの株価

131.88B時価総額

274.76直近12ヶ月PER



Gilead Sciences Inc

105.930

-1.270-1.18%

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. It operates in more than 35 countries worldwide.

企業情報

企業コードGILD

会社名Gilead Sciences Inc

上場日Jan 22, 1992

設立日1987

最高経営責任者「CEO」Mr. Daniel P. O'Day

従業員数17600

証券種類Ordinary Share

決算期末Jan 22

本社所在地333 Lakeside Dr

都市FOSTER CITY

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号94404-1147

電話番号16505743000

ウェブサイトhttps://www.gilead.com/

企業コードGILD

上場日Jan 22, 1992

設立日1987

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Ms. Johanna Mercier

Chief Commercial Officer

92.94K

-1.05%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

26.06K

+6.18%

Ms. Deborah H. (Deb) Telman

Executive Vice President - Corporate Affairs, General Counsel

20.78K

+4.44%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

11.75K

+14.82%

Ms. Kelly A. Kramer

Independent Director

1.34K

Dr. Dietmar P. Berger, M.D., Ph.D.

Chief Medical Officer

Mr. Andrew D. (Andy) Dickinson

Chief Financial Officer

Mr. Harish Manwani

Independent Director

Dr. Ted W. Love, M.D.

Independent Director

Mr. Javier J. Rodriguez

Independent Director

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Ms. Johanna Mercier

Chief Commercial Officer

92.94K

-1.05%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

26.06K

+6.18%

Ms. Deborah H. (Deb) Telman

Executive Vice President - Corporate Affairs, General Counsel

20.78K

+4.44%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

11.75K

+14.82%

Ms. Kelly A. Kramer

Independent Director

1.34K

Dr. Dietmar P. Berger, M.D., Ph.D.

Chief Medical Officer

収益内訳

通貨: USD更新時刻: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

事業別USD

会社名

収益

比率

Biktarvy

13.42B

46.69%

Descovy

2.11B

7.35%

Genvoya

1.76B

6.13%

Sofosbuvir/Velpatasvir

1.59B

5.55%

Yescarta

1.57B

5.46%

Other

8.29B

28.83%

地域別USD

会社名

収益

比率

United States

19.51B

67.84%

Europe

4.35B

15.12%

Other Locations

2.91B

10.11%

事業別

地域別

事業別USD

会社名

収益

比率

Biktarvy

13.42B

46.69%

Descovy

2.11B

7.35%

Genvoya

1.76B

6.13%

Sofosbuvir/Velpatasvir

1.59B

5.55%

Yescarta

1.57B

5.46%

Other

8.29B

28.83%

株主

更新時刻: Thu, May 15

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

9.40%

BlackRock Institutional Trust Company, N.A.

5.68%

State Street Global Advisors (US)

4.79%

Capital Research Global Investors

4.39%

Capital World Investors

4.30%

Other

71.44%

株主統計

比率

The Vanguard Group, Inc.

9.40%

BlackRock Institutional Trust Company, N.A.

5.68%

State Street Global Advisors (US)

4.79%

Capital Research Global Investors

4.39%

Capital World Investors

4.30%

Other

71.44%

種類

株主統計

比率

Investment Advisor

43.34%

Investment Advisor/Hedge Fund

34.71%

Research Firm

2.92%

Pension Fund

2.89%

Hedge Fund

2.04%

Bank and Trust

1.85%

Sovereign Wealth Fund

1.74%

Insurance Company

0.13%

Individual Investor

0.09%

Other

10.29%

機関投資家保有株

更新時刻: Sun, Jan 19

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q1

3341

1.12B

89.83%

-2.17M

2024Q4

3313

1.12B

90.13%

+4.63M

2024Q3

3207

1.10B

88.48%

-11.56M

2024Q2

3188

1.10B

88.24%

-14.37M

2024Q1

3196

1.10B

88.13%

-22.04M

2023Q4

3252

1.11B

88.75%

-8.79M

2023Q3

3190

1.10B

88.14%

-23.58M

2023Q2

3196

1.10B

88.02%

-11.22M

2023Q1

3195

1.09B

87.26%

-11.17M

2022Q4

3203

1.08B

86.64%

+1.09M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

114.97M

9.22%

+203.25K

+0.18%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

74.47M

5.97%

-1.75M

-2.30%

Dec 31, 2024

State Street Global Advisors (US)

60.38M

4.84%

+210.06K

+0.35%

Dec 31, 2024

Capital Research Global Investors

57.95M

4.65%

-3.85M

-6.24%

Dec 31, 2024

Capital World Investors

71.71M

5.75%

-4.84M

-6.33%

Dec 31, 2024

Fidelity Management & Research Company LLC

34.64M

2.78%

+6.42M

+22.73%

Dec 31, 2024

Dodge & Cox

32.95M

2.64%

-98.02K

-0.30%

Dec 31, 2024

Geode Capital Management, L.L.C.

28.29M

2.27%

+749.05K

+2.72%

Dec 31, 2024

Wellington Management Company, LLP

35.66M

2.86%

+1.06M

+3.06%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

25.78M

2.07%

+346.10K

+1.36%

Feb 28, 2025

詳細を見る

関連ETF

更新時刻: Fri, Jun 6

銘柄名

比率

VanEck Biotech ETF

12.74%

Invesco Nasdaq Biotechnology ETF

8.04%

ProShares Ultra Nasdaq Biotechnology

7.64%

iShares Biotechnology ETF

7.08%

Invesco Biotechnology & Genome ETF

5.25%

Invesco Pharmaceuticals ETF

5.19%

ProShares Nasdaq-100 Dorsey Wright Momentum ETF

4.59%

Strategas Macro Momentum ETF

4.45%

USCF Dividend Income Fund

4.26%

First Trust NASDAQ Pharmaceuticals ETF

3.69%

詳細を見る

VanEck Biotech ETF

比率12.74%

Invesco Nasdaq Biotechnology ETF

比率8.04%

ProShares Ultra Nasdaq Biotechnology

比率7.64%

iShares Biotechnology ETF

比率7.08%

Invesco Biotechnology & Genome ETF

比率5.25%

Invesco Pharmaceuticals ETF

比率5.19%

ProShares Nasdaq-100 Dorsey Wright Momentum ETF

比率4.59%

Strategas Macro Momentum ETF

比率4.45%

USCF Dividend Income Fund

比率4.26%

First Trust NASDAQ Pharmaceuticals ETF

比率3.69%

配当金

過去5年間の配当金総支払額は 18.49B 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

Feb 11, 2025

GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Mar 28, 2025 going ex on Mar 14, 2025

Mar 14, 2025

Mar 28, 2025

Mar 14, 2025

Nov 12, 2024

GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024

Dec 13, 2024

Dec 30, 2024

Dec 13, 2024

Aug 13, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024

Sep 13, 2024

Sep 27, 2024

Sep 13, 2024

Apr 26, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024

Jun 14, 2024

Jun 27, 2024

Jun 14, 2024

Feb 06, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024

Mar 15, 2024

Mar 28, 2024

Mar 14, 2024

Nov 08, 2023

GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023

Dec 15, 2023

Dec 28, 2023

Dec 14, 2023

Aug 07, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Sep 28, 2023 going ex on Sep 14, 2023

Sep 15, 2023

Sep 28, 2023

Sep 14, 2023

Apr 28, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Jun 29, 2023 going ex on Jun 14, 2023

Jun 15, 2023

Jun 29, 2023

Jun 14, 2023

Feb 02, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Mar 30, 2023 going ex on Mar 14, 2023

Mar 15, 2023

Mar 30, 2023

Mar 14, 2023

Oct 27, 2022

GILD.NB Final Cash Dividend of gross USD 0.73 paid on Dec 29, 2022 going ex on Dec 14, 2022

Dec 15, 2022

Dec 29, 2022

Dec 14, 2022

詳細を見る

株式分割

日付

種類

比率

データなし

日付

種類

比率

データなし

KeyAI



Gilead Sciences Inc

105.930USD

Gilead Sciences Inc

105.930

概要

企業名